SilicoLife
Start-up Profile
Founded: 2010
Country: Portugal
Number of employees: 15
Main focus areas/active in:
- Strain Development
- Industrial biotechnology
- feed & food
- pharma
- renewable chemicals
Website: www.silicolife.com
Follow us:
Which input provides your business model/core technology towards a bio-based economy?
SilicoLife designs optimized microorganisms and novel pathways for industrial biotechnology applications, based on artificial intelligence and synthetic biology approaches, for the sustainable production of specific target compounds such as chemicals, food ingredients or biopolymers. SilicoLife’s input to the bio-based economy translates into alternative bio-based processes for the production of compounds currently achieved only via chemical synthesis or limited to plant extraction.
Which market/clients do you address and which short-/long-term goals do you have?
We aim to continue to be a key development partner to leading companies across industries and focus on the creation of biological alternatives for the production of chemicals that can benefit from being produced using fermentative processes, tackling high-value applications as pharma, nutrition, supplements and F&F. The company is leading SHIKIFACTORY100, a large collaborative project focused on the development of novel routes from 100+ compounds and is also working with global companies in skincare, materials and synthetic biology.
What makes your approach unique compared to other stakeholders in this field?
SilicoLife’s approach is distinct as it uses rational design methodologies increase the efficiency of our wet lab activities, taking advantage of the latest advances in AI and synthetic biology in combination with biological knowledge. This approach is focused on attacking molecule families in an incremental fashion, reducing the risk of failed attempts by providing valuable alternatives, contributing to the generation of IP from a very early stage.
Get in touch!
Simão Soares
CEO
Please fill out the form below to get in touch with us.
